These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30016491)

  • 41. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dengue vaccines: recent developments, ongoing challenges and current candidates.
    McArthur MA; Sztein MB; Edelman R
    Expert Rev Vaccines; 2013 Aug; 12(8):933-53. PubMed ID: 23984962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dengue pre-vaccination serology screening for the use of Dengvaxia®.
    Hunsperger E; Peeling R; Gubler DJ; Ooi EE
    J Travel Med; 2019 Dec; 26(8):. PubMed ID: 31776549
    [No Abstract]   [Full Text] [Related]  

  • 45. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.
    Guy B
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transmission dynamics of two dengue serotypes with vaccination scenarios.
    González Morales NL; Núñez-López M; Ramos-Castañeda J; Velasco-Hernández JX
    Math Biosci; 2017 May; 287():54-71. PubMed ID: 27773682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dengue vaccine development: strategies and challenges.
    Ramakrishnan L; Pillai MR; Nair RR
    Viral Immunol; 2015 Mar; 28(2):76-84. PubMed ID: 25494228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety concerns derail dengue vaccination program.
    Normile D
    Science; 2017 Dec; 358(6370):1514-1515. PubMed ID: 29269451
    [No Abstract]   [Full Text] [Related]  

  • 49. Dengue Vaccination: Towards a New Dawn of Curbing Dengue Infection.
    Jain S; Vimal N; Angmo N; Sengupta M; Thangaraj S
    Immunol Invest; 2023 Nov; 52(8):1096-1149. PubMed ID: 37962036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention and control of dengue-the light at the end of the tunnel.
    Pang T; Mak TK; Gubler DJ
    Lancet Infect Dis; 2017 Mar; 17(3):e79-e87. PubMed ID: 28185870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.
    Holman DH; Wang D; Raviprakash K; Raja NU; Luo M; Zhang J; Porter KR; Dong JY
    Clin Vaccine Immunol; 2007 Feb; 14(2):182-9. PubMed ID: 17192403
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
    Pitisuttithum P; Bouckenooghe A
    Expert Rev Vaccines; 2016 Jul; 15(7):795-8. PubMed ID: 27171845
    [No Abstract]   [Full Text] [Related]  

  • 53. Development of Sanofi Pasteur tetravalent dengue vaccine.
    Lang J
    Rev Inst Med Trop Sao Paulo; 2012 Oct; 54 Suppl 18():S15-7. PubMed ID: 23011454
    [No Abstract]   [Full Text] [Related]  

  • 54. Vaccination Against Dengue: Challenges and Current Developments.
    Guy B; Lang J; Saville M; Jackson N
    Annu Rev Med; 2016; 67():387-404. PubMed ID: 26515983
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Japanese encephalitis virus prM-E antigen immunization conferred protection against challenge by four different serotypes of Dengue viruses in mice.
    Gao N; Li J; Sheng Z; Chen H; Fan D; Wang P; An J
    Appl Microbiol Biotechnol; 2019 Jun; 103(12):4977-4986. PubMed ID: 31037380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term stability of antibody responses elicited by Dengue virus envelope DIII-based DNA vaccines.
    Slon Campos JL; Poggianella M; Burrone OR
    J Gen Virol; 2018 Aug; 99(8):1078-1085. PubMed ID: 29923817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel vaccination approach for dengue infection based on recombinant immune complex universal platform.
    Kim MY; Reljic R; Kilbourne J; Ceballos-Olvera I; Yang MS; Reyes-del Valle J; Mason HS
    Vaccine; 2015 Apr; 33(15):1830-8. PubMed ID: 25728317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brazil's record dengue surge: why a vaccine campaign is unlikely to stop it.
    Lenharo M
    Nature; 2024 Mar; 627(8003):250-251. PubMed ID: 38429511
    [No Abstract]   [Full Text] [Related]  

  • 60. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.